INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2 H Einsele; S Parekh; D Madduri; B Santomasso; JG Pérez-Larraya; NWV Donk; B Arnulf; M Mateos; KC Braganca; H Varsos; MJ Carrasco-Alfonso; M Akram; N Lendvai; CC Jackson; Y Olyslager; E Zudaire; C Li; D Geng; A Jakubowiak; A Cohen;

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES LJ Costa; NWCJV Donk; L Rosinol; R Popat; Be semer; J Martinez-Lopez; D Trancucci; T Stephenson; K Chastain; N Bahlis;

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES NWCJV Donk; R Popat; L Rosiol; B Besemer; JM Lopez; D Trancucci; R Verona; T Stephenson; K Chastain; N Bahlis;